EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 105 filers reported holding EPIZYME INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $66,908 | -41.5% | 26,763 | +19.7% | 0.00% | -50.0% |
Q3 2021 | $114,447 | -31.9% | 22,353 | +10.5% | 0.00% | 0.0% |
Q2 2021 | $168,028 | -18.9% | 20,220 | -15.0% | 0.00% | -33.3% |
Q1 2021 | $207,159 | -16.9% | 23,784 | +3.7% | 0.00% | -25.0% |
Q4 2020 | $249,161 | -24.3% | 22,943 | -16.9% | 0.00% | -33.3% |
Q3 2020 | $329,280 | -25.7% | 27,601 | 0.0% | 0.01% | -25.0% |
Q2 2020 | $443,272 | +22.4% | 27,601 | +18.2% | 0.01% | 0.0% |
Q1 2020 | $362,143 | -42.2% | 23,349 | -8.4% | 0.01% | -20.0% |
Q4 2019 | $626,734 | +131.9% | 25,477 | -2.8% | 0.01% | +100.0% |
Q3 2019 | $270,315 | +0.6% | 26,206 | +22.4% | 0.01% | 0.0% |
Q2 2019 | $268,657 | +10.8% | 21,407 | +9.4% | 0.01% | +25.0% |
Q1 2019 | $242,472 | +138.0% | 19,570 | +18.3% | 0.00% | +100.0% |
Q4 2018 | $101,893 | -41.9% | 16,541 | 0.0% | 0.00% | -33.3% |
Q3 2018 | $175,335 | -99.9% | 16,541 | 0.0% | 0.00% | -25.0% |
Q2 2018 | $224,131,000 | -20.4% | 16,541 | +4.2% | 0.00% | 0.0% |
Q1 2018 | $281,710,000 | +141462.8% | 15,871 | 0.0% | 0.00% | +33.3% |
Q4 2017 | $199,000 | -65.9% | 15,871 | -48.3% | 0.00% | -25.0% |
Q3 2017 | $584,000 | +26.1% | 30,680 | 0.0% | 0.00% | +33.3% |
Q2 2017 | $463,000 | -12.0% | 30,680 | 0.0% | 0.00% | -25.0% |
Q1 2017 | $526,000 | +41.8% | 30,680 | 0.0% | 0.00% | +33.3% |
Q4 2016 | $371,000 | +37.4% | 30,680 | +11.9% | 0.00% | +50.0% |
Q3 2016 | $270,000 | -15.1% | 27,411 | -11.8% | 0.00% | 0.0% |
Q2 2016 | $318,000 | -15.6% | 31,085 | 0.0% | 0.00% | -33.3% |
Q1 2016 | $377,000 | +14.2% | 31,085 | +50.9% | 0.00% | 0.0% |
Q4 2015 | $330,000 | +24.5% | 20,594 | 0.0% | 0.00% | +50.0% |
Q3 2015 | $265,000 | -48.0% | 20,594 | -3.0% | 0.00% | -50.0% |
Q2 2015 | $510,000 | +164.2% | 21,241 | +106.6% | 0.00% | +300.0% |
Q1 2015 | $193,000 | -0.5% | 10,282 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $194,000 | -30.5% | 10,282 | 0.0% | 0.00% | -50.0% |
Q3 2014 | $279,000 | -12.8% | 10,282 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $320,000 | +91.6% | 10,282 | +147.5% | 0.00% | +100.0% |
Q3 2013 | $167,000 | -21.6% | 4,154 | -45.2% | 0.00% | -50.0% |
Q2 2013 | $213,000 | – | 7,581 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
BP PLC | 24,687 | $28,000 | 0.16% |
NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |